Literature DB >> 25907427

The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes.

Aziz Nazha1, David P Seastone1, Michael Keng1, Sean Hobson1, Matt Kalaycio1, Jaroslaw P Maciejewski2, Mikkael A Sekeres1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25907427     DOI： 10.3109/10428194.2015.1041391

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  7 in total

Review 1.  Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Authors:  Aziz Nazha; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 2.  Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.

Authors:  Aziz Nazha; Rafael Bejar
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 3.  Lower risk but high risk.

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

5.  Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Authors:  A Nazha; M Narkhede; T Radivoyevitch; D J Seastone; B J Patel; A T Gerds; S Mukherjee; M Kalaycio; A Advani; B Przychodzen; H E Carraway; J P Maciejewski; M A Sekeres
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

Review 6.  The MDS genomics-prognosis symbiosis.

Authors:  Aziz Nazha
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

7.  Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Authors:  A Kuendgen; M Nomdedeu; H Tuechler; G Garcia-Manero; R S Komrokji; M A Sekeres; M G Della Porta; M Cazzola; A E DeZern; G J Roboz; D P Steensma; A A Van de Loosdrecht; R F Schlenk; J Grau; X Calvo; S Blum; A Pereira; P Valent; D Costa; A Giagounidis; B Xicoy; H Döhner; U Platzbecker; C Pedro; M Lübbert; I Oiartzabal; M Díez-Campelo; M T Cedena; S Machherndl-Spandl; M López-Pavía; C D Baldus; M Martinez-de-Sola; R Stauder; B Merchan; A List; C Ganster; T Schroeder; M T Voso; M Pfeilstöcker; H Sill; B Hildebrandt; J Esteve; B Nomdedeu; F Cobo; R Haas; F Sole; U Germing; P L Greenberg; D Haase; G Sanz
Journal:  Leukemia       Date:  2020-06-29       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.